AKT1 is an inclusion eligibility criterion in 1 clinical trial for chondrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains AKT1 status and chondrosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

AKT2 is altered in 0.86% of chondrosarcoma patients [2].

AKT2 is an inclusion eligibility criterion in 1 clinical trial for chondrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains AKT2 status and chondrosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

AKT3 is an inclusion eligibility criterion in 1 clinical trial for chondrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains AKT3 status and chondrosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

CCND1 is an inclusion eligibility criterion in 1 clinical trial for chondrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains CCND1 status and chondrosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CCND2 is an inclusion eligibility criterion in 1 clinical trial for chondrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains CCND2 status and chondrosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CCND3 is altered in 0.88% of chondrosarcoma patients [2].

CCND3 is an inclusion eligibility criterion in 1 clinical trial for chondrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains CCND3 status and chondrosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CDK4 is altered in 3.45% of chondrosarcoma patients [2].

CDK4 is an inclusion eligibility criterion in 1 clinical trial for chondrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 status and chondrosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CDK6 is altered in 0.88% of chondrosarcoma patients [2].

CDK6 is an inclusion eligibility criterion in 1 clinical trial for chondrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 status and chondrosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CDKN2A is altered in 10.67% of chondrosarcoma patients [2].

CDKN2A is an inclusion eligibility criterion in 1 clinical trial for chondrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains CDKN2A status and chondrosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CRKL is altered in 0.93% of chondrosarcoma patients [2].

CRKL is an inclusion eligibility criterion in 1 clinical trial for chondrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains CRKL status and chondrosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

EWSR1 is altered in 7.96% of chondrosarcoma patients [2].

EWSR1 is an inclusion eligibility criterion in 1 clinical trial for chondrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains EWSR1 status and chondrosarcoma as inclusion criteria, 1 is phase 2 (1 open) [3].

IDH1 is altered in 22.3% of chondrosarcoma patients [2].

IDH1 is an inclusion eligibility criterion in 3 clinical trials for chondrosarcoma, of which 3 are open and 0 are closed. Of the trials that contain IDH1 status and chondrosarcoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

Ivosidenib has evidence of efficacy in patients with IDH1 mutation in chondrosarcoma [3].

MTOR is altered in 0.87% of chondrosarcoma patients [2].

MTOR is an inclusion eligibility criterion in 1 clinical trial for chondrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains MTOR status and chondrosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PDGFRA is altered in 1.34% of chondrosarcoma patients [2].

PDGFRA is an inclusion eligibility criterion in 1 clinical trial for chondrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA status and chondrosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PIK3CA is altered in 2.58% of chondrosarcoma patients [2].

PIK3CA is an inclusion eligibility criterion in 2 clinical trials for chondrosarcoma, of which 2 are open and 0 are closed. Of the trials that contain PIK3CA status and chondrosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

PIK3CG is altered in 1.06% of chondrosarcoma patients [2].

PIK3CG is an inclusion eligibility criterion in 1 clinical trial for chondrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CG status and chondrosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PIK3R1 is an inclusion eligibility criterion in 1 clinical trial for chondrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3R1 status and chondrosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PIK3R2 is altered in 1.02% of chondrosarcoma patients [2].

PIK3R2 is an inclusion eligibility criterion in 1 clinical trial for chondrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3R2 status and chondrosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PTEN is altered in 2.65% of chondrosarcoma patients [2].

PTEN is an inclusion eligibility criterion in 2 clinical trials for chondrosarcoma, of which 2 are open and 0 are closed. Of the trials that contain PTEN status and chondrosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

RICTOR is altered in 1.04% of chondrosarcoma patients [2].

RICTOR is an inclusion eligibility criterion in 1 clinical trial for chondrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains RICTOR status and chondrosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

RPTOR is altered in 1.01% of chondrosarcoma patients [2].

RPTOR is an inclusion eligibility criterion in 1 clinical trial for chondrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains RPTOR status and chondrosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

TSC1 is an inclusion eligibility criterion in 1 clinical trial for chondrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains TSC1 status and chondrosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

TSC2 is altered in 0.82% of chondrosarcoma patients [2].

TSC2 is an inclusion eligibility criterion in 1 clinical trial for chondrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains TSC2 status and chondrosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].